JP2020521458A - 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 - Google Patents

改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 Download PDF

Info

Publication number
JP2020521458A
JP2020521458A JP2019564951A JP2019564951A JP2020521458A JP 2020521458 A JP2020521458 A JP 2020521458A JP 2019564951 A JP2019564951 A JP 2019564951A JP 2019564951 A JP2019564951 A JP 2019564951A JP 2020521458 A JP2020521458 A JP 2020521458A
Authority
JP
Japan
Prior art keywords
seq
domain
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521458A5 (enExample
Inventor
アーロン・ヤムニウク
メアリー・ストラザーズ
スザンヌ・ジェイ・スシャール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020521458A publication Critical patent/JP2020521458A/ja
Publication of JP2020521458A5 publication Critical patent/JP2020521458A5/ja
Priority to JP2023077286A priority Critical patent/JP2023113636A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019564951A 2017-05-25 2018-05-24 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 Pending JP2020521458A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077286A JP2023113636A (ja) 2017-05-25 2023-05-09 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511245P 2017-05-25 2017-05-25
US62/511,245 2017-05-25
PCT/US2018/034330 WO2018217988A1 (en) 2017-05-25 2018-05-24 MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077286A Division JP2023113636A (ja) 2017-05-25 2023-05-09 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物

Publications (2)

Publication Number Publication Date
JP2020521458A true JP2020521458A (ja) 2020-07-27
JP2020521458A5 JP2020521458A5 (enExample) 2021-07-26

Family

ID=62599725

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564951A Pending JP2020521458A (ja) 2017-05-25 2018-05-24 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物
JP2023077286A Pending JP2023113636A (ja) 2017-05-25 2023-05-09 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077286A Pending JP2023113636A (ja) 2017-05-25 2023-05-09 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物

Country Status (6)

Country Link
US (1) US20200148779A1 (enExample)
EP (1) EP3630832A1 (enExample)
JP (2) JP2020521458A (enExample)
KR (2) KR20200012907A (enExample)
CN (1) CN110637035A (enExample)
WO (1) WO2018217988A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550287A (ja) * 2020-11-02 2023-12-01 アトララス・インコーポレイテッド Ｓａｐ ｆｃ融合タンパク質及び使用方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
DK3468997T5 (da) 2016-06-08 2024-09-09 Xencor Inc Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
KR102713355B1 (ko) 2017-05-25 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 길항작용 cd40 모노클로날 항체 및 그의 용도
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN114599389A (zh) * 2019-08-22 2022-06-07 奇达拉治疗公司 变体fc结构域及其用途
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2021183428A1 (en) * 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
US20230236199A1 (en) * 2020-04-23 2023-07-27 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
WO2021236546A1 (en) 2020-05-18 2021-11-25 Bristol-Myers Squibb Company Antibody variants with improved pharmacokinetic properties
CN112552389B (zh) * 2020-08-07 2023-06-06 中爱瑞祥(杭州)生物科技有限公司 一种活性肽融合蛋白及其制备方法
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2017059196A2 (en) * 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US9051373B2 (en) * 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
KR102713355B1 (ko) * 2017-05-25 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 길항작용 cd40 모노클로날 항체 및 그의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2017059196A2 (en) * 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 9, JPN6022012116, 2001, pages 6591 - 6604, ISSN: 0005128396 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550287A (ja) * 2020-11-02 2023-12-01 アトララス・インコーポレイテッド Ｓａｐ ｆｃ融合タンパク質及び使用方法

Also Published As

Publication number Publication date
KR20200012907A (ko) 2020-02-05
CN110637035A (zh) 2019-12-31
JP2023113636A (ja) 2023-08-16
WO2018217988A9 (en) 2019-05-02
US20200148779A1 (en) 2020-05-14
KR102847736B1 (ko) 2025-08-18
EP3630832A1 (en) 2020-04-08
KR20240095463A (ko) 2024-06-25
WO2018217988A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
KR102847736B1 (ko) 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
US11613585B2 (en) Nucleic acids encoding antagonistic CD40 monoclonal antibodies
CN112566935B (zh) 抗ox40抗体和使用方法
AU2020210635B2 (en) Antibodies against IL-7R alpha subunit and uses thereof
CN113577264B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
TW202033556A (zh) 拮抗性cd40單株抗體及其用途
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
US12435131B2 (en) Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
CN110003338A (zh) 抗ox40抗体及其应用
WO2020112781A1 (en) Antibodies comprising modified heavy constant regions
US20250320268A1 (en) Clinical dosing of sirp1a chimeric protein
WO2021143826A1 (zh) 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
EP4172184A2 (en) Il-10 muteins and fusion proteins thereof
EP4582804A1 (en) Method for screening and preparing immunomodulator
CN115867580A (zh) 具有改进的药代动力学特性的抗体变体
WO2025101811A1 (en) Il-7ra targeting antibodies and uses thereof
EA048273B1 (ru) Антагонистические моноклональные антитела к cd40 и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230620

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230818

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250714